Showing results (41-50 of 51) with videos related to
Sort By:
Pageof 6
Contemporary Clinical Trials Communications|January 25, 2021
A phase I/II study of stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumours (RAPPORT): Clinical trial protocolDavid Pryor, Mathias Bressel, Nathan Lawrentschuk, et al.Journal of Extracellular Vesicles|August 26, 2021
Androgens alter the heterogeneity of small extracellular vesicles and the small RNA cargo in prostate cancerElena S Martens-Uzunova, Gina D Kusuma, Stefania Crucitta, et al.BJU International|May 24, 2021
ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901)Louise Emmett, Shalini Subramaniam, Anthony M Joshua, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 31, 2022
Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfoundKim N Chi, Alan Barnicle, Caroline Sibilla, et al.Plos One|August 13, 2013
The role of Cancer-Testis antigens as predictive and prognostic markers in non-small cell lung cancerThomas John, Maud H W Starmans, Yao-Tseng Chen, et al.Journal of Hematology & Oncology|May 24, 2018
Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trialJun Guo, Jie Jin, Mototsugu Oya, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 20, 2015
A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell CarcinomaSumanta Pal, Arun Azad, Shailender Bhatia, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2026
AI-Based Pathology classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET TrialSebastian Medina, Naoto Tokuyama, Vaishnavi Putcha, et al.The Lancet. Oncology|October 30, 2025
Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trialMatthew Smith, Josep Piulats, Tilman Todenhöfer, et al.European Urology|April 28, 2026
Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 TrialsAlexander D Sherry, Van To, Criselle D'souza, et al.Pageof 6